HIV Treatment at High CD4 Counts Protects Against Both AIDS and Non-AIDS Events in the START Study: Overall and in Subgroup Analyses
July 20, 2015
The international START study produced headline news at IAS 2015 that confirm benefits from starting antiretroviral treatment (ART) at CD4 counts above 500 cells/mm3.
The study also reported no upper CD4 threshold that was protective against AIDS-related events, even thought the overall absolute risk of events was low.
The START study is notable for reporting results 18 months ahead of schedule, following a recommendation by the studies independent Data and Safety Monitoring Board (DSMB) in May that participants in the arm deferring ART until their CD4 count reached 350 cells/mm3 should be offered immediate treatment, and that follow-up should continue as planned for both arms.
The results were presented by Professor Jens Lundgren from University of Copenhagen on behalf of the START study team in two sessions at the conference: an opening plenary on the first day and the International AIDS Society members meeting later in the programme. [1, 2] The study was also simultaneously published online in the New England Journal of Medicine. 
This HTB report combines results from both IAS 2015 and NEJM paper.
Although preliminary findings were released on 27 May 2015 based on the dataset used for the DSMB decision, the expanded results cover three key areas:
Methods and Baseline Characteristics
From December 2009 to December 2013, START randomised 4685 HIV positive treatment-naive adults with CD4 counts >500 cells/mm3 to either an immediate (IMM) or deferred (DEF) ART, with the deferred group waited until the CD4 count reached 350 cells/mm3.
The combined primary endpoint included AIDS related and non-AIDS related complications including grade 4 events and deaths from any cause.
The study included 215 sites in 35 countries, equally divided between high and low/middle income countries. Baseline demographics have already been widely reported and published in online [4, 5] and included approximately 27% women, 55% MSM, and median age 36 years (IQR 29 to 44). Median CD4 and viral load were 651 cells/mm3 (IQR 584 to 765) and 12,700 copies/mL (IQR 3,000 to 43,000), respectively, with no significant differences between groups. At study entry, median time since HIV diagnosis was 1.0 years (IQR: 0.4 to 3.1).
Primary and Key Secondary Endpoint Results
Mean follow-up was 3.0 years (median 2.8; IQR 2.1 to 3.9) with 23% having greater than 4 years follow up. Endpoint results were available for 96% and 95% of the IMM and DEF groups respectively.
By 26 May 2015, 98% vs 48% of the IMM vs DEF participants had started ART (at median CD4 count of 651 vs 408 cells/mm3 respectively). Although ART in the study was provided free from a central repository, and included the choice of all or nearly all approved drugs, the majority of patients in both arms used tenofovir/FTC as background NRTIs (approximately 90%). Efavirenz was the most widely used third component, by 73% and 51% of the IMM vs DEF arms respectively, with atazanavir/r, darunavir/r, rilpivirine and raltegravir making up the majority of other combinations. The study reported high rates of viral suppression with 98% vs 97% of those on treatment having <200 copies/mL at month 12.
The final dataset includes a total of 140 primary endpoint events: 42 (1.8%) in the IMM arm vs 96 (4.1%) in the DEF arm, equivalent to rates of 0.60 vs 1.38 per 100 patient years, respectively. The hazard ratio (HR) for the composite primary endpoint was 0.43 (95% CI: 0.30 to 0.62), significantly in favour of the IMM group, p<0.001. Hazard ratios for other key secondary endpoints also significantly favoured the IMM group: 0.28 (95%CI: 0.15 to 0.50) for serious AIDS-related events (p<0.001) and 0.61 (95%CI: 0.38 to 0.97, p=0.04) for serious non-AIDS-related. There was no significant difference between groups for all cause mortality: HR 0.58 (95%CI: 0.28-1.17, p=0.13). See Table 1.
An unexpected outcome in START is the degree to which AIDS events were more common at high CD4 counts than non-AIDS. Throughout the study it was expected that the greatest impact would be to reduce inflammation-related events. Also, consistent with the planned study design, only 4% of follow-up time in the deferred arm occurred at a CD4 count <350 cells/mm3 an accounted for only 5 primary events.
The most common events were cardiovascular disease (29% vs 15%), non-AIDS cancers (21% vs 19%) and tuberculosis (14% vs 20%) in the IMM vs DEF groups respectively.
Endpoints that were significantly reduced in the IMM group included tuberculosis (HR 0.29; 95%CI: 0.12 to 0.73), p=0.008) and Kaposi's Sarcoma (HR 0.09; 95%CI: (0.01 to 0.71, p=0.02) but not malignant lymphoma (p=0.07), non-AIDS cancers (p=0.09), cardiovascular disease (p=0.65), Grade 4 events (p=0.97), unscheduled hospitalisation (p=0.28) and combined Grade 4 event, unscheduled hospitalisation, or death from any cause (p=0.25). See Table 2.
This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.